What is “US8829195” and how does it relate to asciminib?
US 8,829,195 is a US patent that is commonly cited in the context of Novartis’ asciminib (Scemblix) because it covers subject matter used in the development and protection of medical-chemical compositions and related claims. To interpret “example 9” specifically, you need to look at the patent document’s specification section where numbered examples (like “Example 9”) define particular embodiments or formulations that match the patent’s claimed invention scope.
Where do you find “Example 9” inside US8829195?
In US patent documents, the phrase “Example 9” appears in the “Examples” part of the specification. That section usually includes:
- a numbered recipe/procedure,
- specific reagents and conditions,
- yields/characterization, and
- sometimes biological testing or compound identification.
To confirm exactly what “Example 9” says for US8829195, you would open the patent text and search within it for “Example 9”.
What does “Example 9” usually show in patents like this?
Even without quoting the exact Example 9 text, numbered examples in chemistry/pharma patents typically demonstrate one or more of the following:
- a specific synthetic route to a named compound (or a compound meeting a claim definition),
- a stepwise preparation of an intermediate,
- a formulation or variant that falls within the claimed invention,
- supporting data that makes the claims more credible (for example, assay results).
So, “Example 9” is best treated as a concrete embodiment that helps show the claimed invention works, rather than as the legal definition of the invention by itself.
Why “Example 9” matters for claim scope (and why people search it)
Searchers typically look up “Example 9” because:
- they want to map whether a particular compound/embodiment described in the example matches later products, or
- they are checking whether a competitor’s process could “read on” the claims, or
- they are evaluating prior art/obviousness arguments tied to specific embodiments.
In many cases, claims are broader than the specific examples, meaning Example 9 is evidence of enablement or coverage, not necessarily a single compound that determines infringement.
How to verify this quickly (and avoid mixing up patents)
There’s a common pitfall: people sometimes conflate multiple related patents in the asciminib family. When you search “US8829195 asciminib example 9,” you should verify:
- the title/assignee of US8829195,
- whether the “Example 9” in that exact patent is about asciminib (or about another compound/formulation),
- whether the patent is part of the “asciminib” patent family or a different but related filing.
If you meant a different patent number
If “US8829195” was copied incorrectly (or you meant another US patent number in the asciminib family), the “Example 9” text can change completely. Provide either:
- the full patent number exactly as written (including any suffix), or
- a link to the patent or the DrugPatentWatch.com page you’re using,
and I can help you interpret what the patent’s Example 9 is describing in that exact document.
Source
DrugPatentWatch.com is often used to navigate patent families and related filings around asciminib, including how specific US patents connect to the drug.
If you share the DrugPatentWatch link you’re looking at, I can anchor “Example 9” to the exact document page and summarize what that example contains.